LETTER Archives - Page 2 of 4 - World Asthma Foundation

July 1, 2014

GSK and Theravance submit US sNDA for Breo Ellipta in asthma – The Pharma Letter

GSK and Theravance submit US sNDA for Breo Ellipta in asthma
The Pharma Letter
Today's filing is based on data generated from the comprehensive clinical development program for FF/VI in asthma. The clinical development program comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients …
Glaxo, Theravance File Asthma Drug Application with FDANASDAQ
Glaxo submits new drug application for asthma treatmentIFA Magazine
GSK and Theravance Announce Submission to US Regulatory Authorities for …MarketWatch
RTT News
all 15 news articles »

View full post on asthma – Google News

February 10, 2014

Skyepharma launches Flutiform in France for asthma – The Pharma Letter

Skyepharma launches Flutiform in France for asthma
The Pharma Letter
UK drug delivery specialist Skyepharma (LSE: SKP) has received regulatory approval and agreement on pricing reimbursement for asthma treatment Flutiform in France. Skyepharma's licensee Mundipharma, responsible for the development and …
Skyepharma Jumps As It Launches Flutiform in FranceLondon South East

all 2 news articles »

View full post on asthma – Google News

August 1, 2013

LETTER: Don’t think asthma is a simple disease – Lehighvalleylive.com

LETTER: Don't think asthma is a simple disease
Lehighvalleylive.com
For too long, asthma has been thought of by too many people as something of a minor disease. I don't mean that doctors who treat asthma patients don't take their care seriously. I personally treat patients with severe asthma, and my patients and I are …

View full post on asthma – Google News

July 24, 2013

Shares jump as Array BioPharma reports positive results for asthma drug – The Pharma Letter

Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter
US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said …

View full post on asthma – Google News

June 16, 2013

Global asthma market to reach 159 million lifetime cases by 2022 – The Pharma Letter

Global asthma market to reach 159 million lifetime cases by 2022
The Pharma Letter
Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion. While drugs to manage asthma have existed for several decades, pharmaceutical companies have developed faster acting and more effective products over …

View full post on asthma – Google News

April 10, 2013

US pulmonologists view refractory asthma patient treatment with biosimilar … – The Pharma Letter

US pulmonologists view refractory asthma patient treatment with biosimilar …
The Pharma Letter
US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent of their severe, refractory asthma patients are treated with Genentech and Novartis' Xolair (omalizumab), the only approved drug that serves this …

View full post on asthma – Google News

February 25, 2013

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma … – The Pharma Letter

Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter
German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology …
Boehringer Ingelheim drug shows benefits in new asthma trialZenopa

all 2 news articles »

View full post on asthma – Google News

December 14, 2012

Letter: Health article needlessly scared asthma patients – SouthCoastToday.com

Letter: Health article needlessly scared asthma patients
SouthCoastToday.com
It is unfortunate that the article (was) written one-sided, mostly in medical terms that did not adequately distinguish the value that many drugs in this class, including Advair, have advanced the treatment of asthma. As one of the original researchers …

View full post on asthma – Google News

November 27, 2012

Asthma preventive drugs market led by GlaxoSmithKline’s Advair – The Pharma Letter

Asthma preventive drugs market led by GlaxoSmithKline's Advair
The Pharma Letter
Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers …

View full post on asthma – Google News

October 3, 2012

LETTER: On A Coal-Free Connecticut – Hartford Courant

LETTER: On A Coal-Free Connecticut
Hartford Courant
I was born and raised in Bridgeport and I, like many of my neighbors, have asthma. Our asthma rate has skyrocketed in comparison to neighboring towns and our coal plant, operating on some of the hottest days of the year, has been a huge factor in this …

and more »

View full post on asthma – Google News